Lisa L. Mueller, J.D., B.S.
For over twenty-five years, Lisa has provided strategic counsel on complex patent issues to clients in the pharmaceutical, biopharmaceutical, biotechnology and chemistry sectors. She brings an in-depth knowledge and extensive experience to her work advising clients on the global patent protection, freedom to operate and validity of blockbuster drugs they aim to produce and distribute.
With a background in chemistry and biology, Lisa provides advice on the full spectrum of global intellectual property portfolio management including patent prosecution, opposition and other post-grant proceedings, and diverse regulatory matters in the following areas:
• Small molecules and biologics
• Drug delivery and drug preparation methods
• Diagnostics and personalized medicine
• Physical and materials sciences
• Food science and nutrition
• Renewable/green chemistry
• Polymer chemistry
• Agricultural, ornamental, vegetable and tree breeding and development (including plant patents and plant variety protection)
Since 2001, Lisa has worked closely with in-house legal departments of global pharmaceutical firms regarding their patent development and enforcement strategies. In this partnership, she provides training to new in-house counsel and meets with scientists and other business development to anticipate and resolve a wide array of problems including navigation of U.S. Food and Drug Administration approval.
A thought leader on pharmaceutical and biopharmaceutical patent law, Lisa speaks frequently to legal and industry groups, and publishes widely. She was the author of an award-winning blog, BRIC Wall, which provides unique insights on patent law developments in the life sciences industry in Brazil, Russia, India and China. Lisa is currently the author of the blog, BRICS & Beyond (https://bricsandbeyond.blog/) which provides unique insights on patent law developments in the life sciences industry not only in Brazil, Russia, India and China but in other countries outside of the United States.
Professional Experience
Shareholder, Casimir Jones S.C., 2018-present
Partner, Michael Best & Friedrich LLP, 2011-2018
Partner, Polsinelli Shughart, 2009-2011
Partner, Dykema Gossett PPC, 2007-2009
Partner, Wood Phillips, 2002-2006
Education
Valparaiso University School of Law, J.D. (magna cum laude,), 1992
Valparaiso University, Chemistry and Biology, B.S., 1985
Admitted
State Bar of Illinois
United States Patent and Trademark Office
U.S. District Court, N.D. of Illinois
Publications and Speaking Engagements
BRICS & BEYOND BLOG
April 25, 2018
Brazilian Mailbox Patents: Big Loss for Alexion
BRICS & BEYOND BLOG
April 19, 2018
Patent Term Extension is Becoming a Reality in China
BRICS & BEYOND BLOG
April 18, 2018
Protecting Life Science Inventions in the Arabian Gulf States – Part 1: Saudi Arabia
BRIC WALL BLOG
February 12, 2018
Working Statements in India: Are You Compliant? – Update
BRIC WALL BLOG
January 21, 2018
Working Statements in India: Are you Compliant?
BRIC WALL BLOG
January 8, 2018
Hitting the Ground Running: The Brazilian Patent Office Publishes New Guidelines Relating to the Examination of Chemical Inventions
BRIC WALL BLOG
December 22, 2017
Draft Intellectual Property Policy of the Republic of South Africa – Phased Implementation – Phase 2 – Part IV
BRIC WALL BLOG
December 08, 2017
Draft Intellectual Property Policy of the Republic of South Africa – Phased Implementation – IP and Public Health – Part III
BRIC WALL BLOG
December 04, 2017
Draft Intellectual Property Policy of the Republic of South Africa – Strategies and Key Reforms – Part II
BRIC WALL BLOG
November 30, 2017
Mexico Faces Renewed Pressure to Implement the 1991 Act of the UPOV Convention
BRIC WALL BLOG
November 28, 2017
Healthcare Reform in the Ukraine and Investment Opportunities for the Private Sector
BRIC WALL BLOG
November 22, 2017
Draft Intellectual Property Policy of the Republic of South Africa – Introduction and Goals
BRIC WALL BLOG
November 22, 2017
The Patent Prosecution Highway (PPH) Pilot Program and the Brazilian PTO – Recent Updates
WEBINAR:
November 09, 2017
Global Patent Strategies for Protecting Plants & Agricultural Products
WEBINAR:
November 01, 2017
Drug Repurposing
BRIC WALL BLOG
November 01, 2017
Understanding Brazil’s Service Guideline #37 for the Examination of Patent Applications Claiming Pharmaceutical Products and Processes
BRIC WALL BLOG
October 25, 2017
Good News in China – Faster Approval for Innovative New Drugs Is on the Way
BRIC WALL BLOG
September 29, 2017
Understanding Bolar and Bolar-Like Exceptions in the U.S. and Abroad – Part 3- Mexico
BRIC WALL BLOG
September 01, 2017
After Years of Waiting, Your or Your Competitor’s Patent Application May Quickly Issue in Brazil. Are You Ready?
BRIC WALL BLOG
August 22, 2017
Understanding Bolar and Bolar-Like Exceptions in the U.S. and Abroad – Part 2 – Canada
BRIC WALL BLOG
July 20, 2017
Understanding Bolar and Bolar-Like Exceptions in the U.S. and Abroad – Part 1
BRIC WALL BLOG
June 26, 2017
Essential Diagnostics Lists to be Developed by WHO
EVENT
ACI Biosimilars Conference, NY, NY
June 14, 2017
Biosimilars around the World: Examining Challenges and Strategies for Creating an International
Biosimilar Portfolio
BRIC WALL BLOG
June 02, 2017
Amendments to the Grace Period in Taiwan for Novelty and Inventive Step
Webinar
May 03, 2017
Subject Matter Eligibility: Avoiding § 101 Issues in Protecting Life Science Inventions & The State of Software Patents Three Years After Alice
BRIC WALL BLOG
April 25, 2017
New guidelines in Brazil give more power to ANVISA in the examination of pharmaceutical patent applications
BRIC WALL BLOG
April 10, 2017
Brazil: Courts confirm preliminary injunction based on pending patent applications
Webinar
February 23, 2017
An Overview of the 21st Century Cures Act
BRIC WALL BLOG
February 09, 2017
Changes to the IP Landscape in Turkey-Industrial Designs
BRIC WALL BLOG
February 02, 2017
Changes to the IP Landscape in Turkey – Patents and Utility Models
BRIC WALL BLOG
January 16, 2017
Two Important Decisions Addressing ANVISA’s Prior Approval of Pharmaceutical Patents in Brazil
BRIC WALL BLOG
January 06, 2017
Delhi High Court Strikes Down Section 24(5) of the Plant Varieties Act as Unconstitutional
BRIC WALL BLOG
December 26, 2016
Property Rights Protection Guideline Released in China
BRIC WALL BLOG
November 29, 2016
Update on Patentability of Diagnostic Claims: Canada (Part 3 of an 8-part Series)
Webinar
November 15, 2016
Patent Prosecution and Enforcement in Turkey, Saudi Arabia, South Africa, Algeria, and Egypt
BRIC WALL BLOG
November 06, 2016
New Requirements in Brazil for Plant Variety Protection Applications in View of Brazil’s Biodiversity Law
BRIC WALL BLOG
October 20, 2016
A Review of Compulsory Licenses in Colombia
BRIC WALL BLOG
October 03, 2016
Ukraine’s Competition Authority Issues a Major Decision on Drug Pricing Practices
PUBLICATION
September 26, 2016
The Effect of FTC Challenges to Pay-For-Delay Agreements: Brand-Name and Generic Companies
Abandon Large Cash Payments and Other Forms of Reverse Payments (American Pharmaceutical Review: https://www.americanpharmaceuticalreview.com/Featured-Articles/190995-The-Effect-of-FTC-Challenges-to-Pay-For-Delay-Agreements-Brand-Name-and-Generic-Companies-Abandon-Large-Cash-Payments-and-Other-Forms-of-Reverse-Payments/)
BRIC WALL BLOG
September 23, 2016
Amendments to Indonesian Patent Law Come into Effect
BRIC WALL BLOG
September 23, 2016
Accelerated Examination of Patent Applications in Argentina
BRIC WALL BLOG
August 29, 2016
Amendments to Indonesian Patent Law Come into Effect
BRIC WALL BLOG
August 19, 2016
Updates to the Brazilian Food and Drug Administration OTC Drug Guidelines
BRIC WALL BLOG
August 05, 2016
Update on Patentability of Diagnostic Claims: Brazil (Part 2 of an 8-part Series)
BRIC WALL BLOG
July 20, 2016
Update on Patentability of Diagnostic Claims: Australia (Part 1 of an 8-part Series)
WEBINAR
July 12, 2016
Patent Prosecution and Enforcement in Thailand, Indonesia, Vietnam, Malaysia and Singapore
BRIC WALL BLOG
June 30, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Argentina
BRIC WALL BLOG
June 27, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Thailand
BRIC WALL BLOG
June 15, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Venezuela
BRIC WALL BLOG
June 13, 2016
India’s Stringent and Shifting Policy on Genetically Modified Cotton Seeds
BRIC WALL BLOG
June 03, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Chile
BRIC WALL BLOG
June 02, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Brazil
BRIC WALL BLOG
May 25, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Algeria and Kuwait
BRIC WALL BLOG
May 23, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in China
BRIC WALL BLOG
May 16, 2016
The much awaited Indian National IPR Policy has arrived!
BRIC WALL BLOG
May 16, 2016
IPO’s patent to Gilead’s Sovaldi challenged at Delhi High Court
BRIC WALL BLOG
May 13, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in India
Webinar
May 10, 2016
Patent Prosecution and Enforcement in Mexico, Colombia and Chile
BRIC WALL BLOG
May 06, 2016
An Overview of the USTR’s 2016 Special 301 Report on the State of IPR in Russia
Webinar
May 04, 2016
Foreign Filing Restrictions and Licenses
BRIC WALL BLOG
May 02, 2016
An Overview of the USTR’s 2016 Special 301 Report
BRIC WALL BLOG
April 21, 2016
India Patent Office Decision Denying Cipla’s Patent Application for an Anti-Retroviral Combination
BRIC WALL BLOG
March 29, 2016
Expediting Patent Prosecution in Brazil
WEBINAR
March 15, 2016
Patent Prosecution and Enforcement in Brazil, Russia, India and China
BRIC WALL BLOG
March 09, 2016
Roche v. Biocad – Patent litigation likely to shape Russia’s IP landscape
BRIC WALL BLOG
March 04, 2016
Notification Date of Marketing Approval to be used in calculating PTE duration in Israel
BRIC WALL BLOG
February 25, 2016
The Turkish Intellectual Property Court Rules on the Patentability of Genes and Other Nucleic Acid Sequences
BRIC WALL BLOG
February 16, 2016
Brazilian Patent Office and the Patent Prosecution Highway Program
BRIC WALL BLOG
February 08, 2016
Foreign Filing Restrictions and Licenses in Russia – Part 4
BRIC WALL BLOG
January 29, 2016
Foreign Filing Restrictions and Licenses in India – Part 3
BRIC WALL BLOG
January 19, 2016
Foreign Filing Restrictions and Licenses in China – Part 2
BRIC WALL BLOG
January 12, 2016
Foreign Filing Restrictions and Licenses in the U.S. – Part 1
BRIC WALL BLOG
January 08, 2016
Biologics and Biosimilars Bits and Bytes – January 8, 2016
BRIC WALL BLOG
December 30, 2015
Current State of Data Protection and Exclusivity in Russia
BRIC WALL BLOG
December 14, 2015
Merck’s Ezetrol and Patent Term Extension in Israel
BRIC WALL BLOG
December 10, 2015
Biologics and Biosimilars Bits and Bytes – December 10, 2015
BRIC WALL BLOG
November 30, 2015
Biologics and Biosimilars Bits and Bytes – November 30, 2015
BRIC WALL BLOG
November 22, 2015
TPP and the Continuing Controversy Over the Exclusivity Period for Biologics
BRIC WALL BLOG
November 13, 2015
Brazilian Patent and Trademark Office Publishes New Rule on the Prioritization Examination of Patent
Applications
BRIC WALL BLOG
November 05, 2015
A Review of the Patent Related Provisions of the TPP – Patent Revocation, Publication and Delays
BRIC WALL BLOG
October 28, 2015
Brazil: Federal District Court in Rio de Janeiro Declares AstraZeneca’s Patent Covering Fosladex Invalid
BRIC WALL BLOG
October 19, 2015
It’s Status Quo for Now: Federal Circuit Denies Petition for Rehearing En Banc in Amgen v. Sandoz
BRIC WALL BLOG
October 14, 2015
A Review of the Patent Related Provisions of the TPP – Patentable Subject Matter and Grace Periods
BRIC WALL BLOG
October 05, 2015
Jordan FDA Issues a Guideline for the Registration of Biosimilars
BRIC WALL BLOG
September 25, 2015
Amgen is at it Again – Sues Hospira For Not Wanting to Dance Over its Biosimilar
BRIC WALL BLOG
September 18, 2015
Indian Patent Office Rejects Pfizer’s Patent for Tofacitinib – Again!
BRIC WALL BLOG
September 10, 2015
Divisional Applications and the Patent Prosecution Highway Program between U.S. and Mexico
BRIC WALL BLOG
September 02, 2015
Update in Amgen v. Sandoz
BRIC WALL BLOG
August 12, 2015
New Guidelines for the Examination of Polymorph and Salt Patents Issued by the Israeli Patent and Trademark Office
BRIC WALL BLOG
August 03, 2015
Can the Minimum Period of 5 years Established by NAFTA for Regulatory Data Exclusivity be Extended in Mexico for Biological Medical Products?
BRIC WALL BLOG
July 29, 2015
A New Beginning? The Brazilian Patent and Trademark Office has a New President.
BRIC WALL BLOG
July 23, 2015
The Riddle Wrapped in a Mystery Inside an Enigma – The Federal Circuit Decides Amgen v. Sandoz – Is Anyone Happy?
BRIC WALL BLOG
July 14, 2015
New Patent Examination Guidance in Canada for Evaluating Medical Diagnostic Methods: Will Canada’s Application Be More Flexible than the U.S.?
BRIC WALL BLOG
July 07, 2015
Brazil: Strategies and Trends on Intellectual Property Technology Law and Litigation
BRIC WALL BLOG
June 30, 2015
AstraZeneca’s Crestor® Patent is Invalidated by the Brazilian Federal Courts
BRIC WALL BLOG
June 26, 2015
13th Federal District Court of Rio de Janeiro Holds that ANVISA Can Examine Patentability Requirements of Patent Applications Claiming Pharmaceutical Inventions
BRIC WALL BLOG
June 14, 2015
Ariosa Diagnostics, Inc. v. Sequenom, Inc. – Another Diagnostic Patent Meets its End
BRIC WALL BLOG
June 07, 2015
Federal Circuit Hears Oral Arguments in Litigation Involving the First U.S. Biosimilar Product
BRIC WALL BLOG
June 06, 2015
Brazil’s New Biodiversity Law
BRIC WALL BLOG
May 20, 2015
Strategies for Successfully Mastering the Different Challenges of the IP Systems in the BRIC Countries and U.S. in the Pharmaceutical and Life Sciences Sectors
BRIC WALL BLOG
May 11, 2015
Third Party Observations in China – Part 7 of an 8 Part Series
BRIC WALL BLOG
April 27, 2015
Approval of the First Biosimilar Monoclonal Antibody in Brazil
BRIC WALL BLOG
April 27, 2015
Pre-Grant Submissions and Post-Grant Review Proceedings in Brazil – Part 6 of an 8 Part Series
BRIC WALL BLOG
April 19, 2015
Third Party Observations in Europe – Part 5 of an 8 Part Series
BRIC WALL BLOG
April 09, 2015
Third Party Submissions in the U.S. – Part 4 of an 8 Part Series
BRIC WALL BLOG
April 02, 2015
Pre- and Post-Grant Oppositions in India – Part 3 of an 8 Part Series
BRIC WALL BLOG
March 23, 2015
Third Party Submissions in Russia – Part 2 of an 8 Part Series
BRIC WALL BLOG
March 15, 2015
Brazil mailbox litigation update: First case to be heard by the Federal Court of Appeals on March 24, 2015
BRIC WALL BLOG
March 08, 2015
U.S. FDA Approves the First Biosimilar Product
BRIC WALL BLOG
March 06, 2015
Post-Grant Oppositions in Japan – Part 1 of an 8 Part Series
BRIC WALL BLOG
March 06, 2015
Post-Grant Review Proceedings, Oppositions and Third-Party Observations in the U.S., BRIC and other Non-BRIC Countries: An Introduction
BRIC WALL BLOG
February 27, 2015
Taking Advantage of Brazil’s Green Patent Pilot Program
BRIC WALL BLOG
February 15, 2015
Revised Seed Law Expected to Come into Effect Soon in China
BRIC WALL BLOG
February 15, 2015
The Thorny Problem of Patentable Eligible Subject Matter: Part 8 of a 10-Part Series: Australia – A Further Update
BRIC WALL BLOG
February 05, 2015
Is compulsory licensing of generic medicines coming to the Russian Federation?
BRIC WALL BLOG
January 29, 2015
Brazil mailbox litigation update: Good news to start the year for the pharmaceutical industry
BRIC WALL BLOG
January 22, 2015
The Copaxone Story in the U.S. and India: U.S. Supreme Court Decision
BRIC WALL BLOG
January 15, 2015
5 Lessons From FDA’s First Biosimilar Review
BRIC WALL BLOG
January 12, 2015
Inching Closer to the First Biosimilar Approval in the U.S.
BRIC WALL BLOG
January 04, 2015
Be Mindful of Your Claims in Divisional Applications and Patents in South Africa
BRIC WALL BLOG
December 21, 2014
A new list of strategic products creates opportunities for companies in Brazil
BRIC WALL BLOG
December 11, 2014
2014 Year in Review of U.S. Biosimilar Activity
BRIC WALL BLOG
December 07, 2014
The Breadth of India’s “Bolar Exemption”
BRIC WALL BLOG
November 27, 2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 3 of a 5-Part Series
BRIC WALL BLOG
November 19, 2014
A Report from the “Biosimilars and Biotech: MENA Conference” in Istanbul, Turkey: Part 1
BRIC WALL BLOG
November 17, 2014
Biosimilars and Biotech: MENA Conference – Istanbul, Turkey – November 18-19th
WEBINAR
November 12, 2014
Navigating the Small Molecule and Formulation Obviousness Highway in View of Recent Federal Circuit Decisions
BRIC WALL BLOG
November 06, 2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 2 of a 5-Part Series
BRIC WALL BLOG
November 06, 2014
The Brazilian Patent Office places the fight against the patent application backlog as its top priority
BRIC WALL BLOG
October 27, 2014
A Review of the Status of Biosimilars in the U.S.
BRIC WALL BLOG
October 22, 2014
First Mailbox Appeal to be decided by the Federal Court of Appeals in Brazil: An Update
BRIC WALL BLOG
October 14, 2014
First Mailbox Appeal to be decided by the Federal Court of Appeals in Brazil
BRIC WALL BLOG
October 06, 2014
Patent Term Adjustment: Not available solely in the U.S.
BRIC WALL BLOG
September 22, 2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 1 of a 5-Part Series
BRIC WALL BLOG
September 16, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 10 of a 10-Part Series: Japan
BRIC WALL BLOG
September 11, 2014a
The Thorny Problem of Patentable Eligible Subject Matter: Part 9 of a 10-Part Series: South Africa
BRIC WALL BLOG
September 05, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 8 of a 10-Part Series: Australia – Update
BRIC WALL BLOG
August 28, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 8 of a 10-Part Series: Australia
BRIC WALL BLOG
August 18, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 7 of a 10-Part Series: China
BRIC WALL BLOG
August 05, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 6 of a 10-Part Series: Europe
BRIC WALL BLOG
July 30, 2014
The Race is on! Anxiously Waiting for the First U.S. Biosimilar to Cross the Finish Line
BRIC WALL BLOG
July 24, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 5 of a 10-Part Series: Brazil
BRIC WALL BLOG
July 16, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 4 of a 10-Part Series: Russia
BRIC WALL BLOG
July 10, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 3 of a 10-Part Series: India
BRIC WALL BLOG
July 08, 2014
Patent Troll Update: Brazil
BRIC WALL BLOG
June 25, 2014
Is an Abbreviated Pathway for Biosimilars Coming Soon to China?
BRIC WALL BLOG
June 20, 2014
Availability of Biosimilar Pathways and Data/Marketing Exclusivity Globally: Update
BRIC WALL BLOG
June 13, 2014
Cloning: It’s not what you think – Changes to ANVISA’s “clone” procedure
BRIC WALL BLOG
June 04, 2014
Availability of Biosimilar Pathways and Data/Marketing Exclusivity Globally
BRIC WALL BLOG
May 29, 2014
An Overview of Biosimilars in the Russian Federation
BRIC WALL BLOG
May 21, 2014
An Overview of Biosimilars and the Biosimilar Pathway in India
BRIC WALL BLOG
May 11, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Update to Part 1 of the 10-Part Series: U.S.
BRIC WALL BLOG
May 09, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 2 of a 10-Part Series: Canada
BRIC WALL BLOG
April 30, 2014
The Thorny Problem of Patentable Eligible Subject Matter: Part 1 of a 10-Part Series: U.S
BRIC WALL BLOG
April 23, 2014
The Copaxone Story in the U.S. and India: To Stay or Not to Stay is the Question
BRIC WALL BLOG
April 14, 2014
The Thorny Problem of Patentable Eligible Subject Matter: An Introduction
BRIC WALL BLOG
April 09, 2014
The Copaxone Story in the U.S. and India: A Further Update
BRIC WALL BLOG
April 04, 2014
The Copaxone Story in the U.S. and India: An Update
BRIC WALL BLOG
April 01, 2014
Divisional Practice in the BRICs and Other Countries – Part 9 of a 9-Part Series: A Comprehensive
Summary
BRIC WALL BLOG
March 26, 2014
Protecting and Enforcing Trade Secrets in China
BRIC WALL BLOG
March 19, 2014
Divisional Practice in the BRICs and Other Countries – Part 8 of a 9-Part Series: Europe
BRIC WALL BLOG
March 14, 2014
BRIC-a-BRAC: March 14, 2014
BRIC WALL BLOG
March 12, 2014
Understanding Obviousness in Pakistan
BRIC WALL BLOG
March 05, 2014
The Copaxone Story in the U.S. and India
BRIC WALL BLOG
February 26, 2014
Clarity regarding the use of Post-Filing Data in China?
BRIC WALL BLOG
February 24, 2014
Patent Trolls: A View from Europe
BRIC WALL BLOG
February 19, 2014
Patent Troll Update: Japan
BRIC WALL BLOG
February 16, 2014
Patent Trolls: A Global Perspective
BRIC WALL BLOG
February 11, 2014
Pay Your Annuities in Brazil!
BRIC WALL BLOG
February 06, 2014
Divisional Practice in the BRICs and other Countries – Part 7 of a 9-Part Series: Canada
BRIC WALL BLOG
February 05, 2014
BRIC-a-BRAC: February 5, 2014
BRIC WALL BLOG
January 31, 2014
BRIC-a-BRAC: January 31, 2014
BRIC WALL BLOG
January 29, 2014
Divisional Practice in the BRICs and other Countries – Part 6 of a 9-Part Series: China
BRIC WALL BLOG
January 24, 2014
BRIC-a-BRAC: January 24, 2014
BRIC WALL BLOG
January 21, 2014
Regulatory Pathway for Biosimilar Products in Nigeria
BRIC WALL BLOG
January 20, 2014
BRIC-a-BRAC
BRIC WALL BLOG
January 17, 2014
BRIC-a-BRAC
BRIC WALL BLOG
January 15, 2014
Time Period and Burden of Proof Requirements when Requesting Revocation of a Patent in Kenya
BRIC WALL BLOG
January 10, 2014
BRIC-a-BRAC
BRIC WALL BLOG
January 07, 2014
Has Inequitable Conduct Come to India?
BRIC WALL BLOG
January 06, 2014
BRIC-a-BRAC
BRIC WALL BLOG
January 01, 2014
Helping Clients Understand Biosimilar Product Regulations and the Biosimilar Litigation Process
BRIC WALL BLOG
December 24, 2013
Brazil’s Ministry of Health Issues New List of “Strategic” Drugs
BRIC WALL BLOG
December 18, 2013
Divisional Practice in the BRICs and other Countries – Part 5 of a 9-Part Series: Russia
BRIC WALL BLOG
December 10, 2013
Divisional Practice in the BRICs and other Countries – Part 4 of a 9-Part Series
BRIC WALL BLOG
December 02, 2013
Divisional Practice in the BRICs and other Countries – Part 3
BRIC WALL BLOG
November 21, 2013
Divisional Practice in the BRICs and other Countries – Part 2
BRIC WALL BLOG
November 13, 2013
Divisional Practice in the BRICs and other Countries – Part 1
BRIC WALL BLOG
November 09, 2013
Should ANVISA be Permitted to Reject Pharmaceutical Patent Applications in Brazil?
BRIC WALL BLOG
November 07, 2013
Is the Patent Term “Guarantee” in Brazil Unconstitutional?
BRIC WALL BLOG
November 03, 2013
Request for Public Comments by ANVISA on the Interchangeability of Branded Generic Drugs with Reference Drugs in Brazil
BRIC WALL BLOG
October 29, 2013
Nigeria Patent Protection: The Basics – Part 2 of a 2-Part Series
BRIC WALL BLOG
October 16, 2013
Nigeria Patent Protection: The Basics – Part 1 of a 2-Part Series
BRIC WALL BLOG
October 14, 2013
Recent Brazilian Jurisprudence Concerning the Scope of ANVISA’s Prior Consent
BRIC WALL BLOG
October 01, 2013
The Problem of Mailbox Patents and Patent Term in Brazil
BRIC WALL BLOG
September 30, 2013
Availability of Biosimilar Pathways and Data Exclusivity in Asian, Latin American and Eastern European Countries
BRIC WALL BLOG
September 18, 2013
Patentees Can Continue Patent Infringement Lawsuits in Russia Even if a Patent is Found to Be Partially Invalid
BRIC WALL BLOG
September 12, 2013
Understanding Biologics and Biosimilars in Turkey
BRIC WALL BLOG
September 04, 2013
Understanding Biologics and Biosimilars in Brazil
BRIC WALL BLOG
August 26, 2013
Section 8 of the Indian Patents Act and a Comparison with the Disclosure Requirements in Canada, Israel and the U.S.
BRIC WALL BLOG
August 08, 2013
Recent Decisions involving Section 3(d) of the Indian Patents Act
BRIC WALL BLOG
August 08, 2013
The Elusive Patent Expiration Date
BRIC WALL BLOG
July 23, 2013
Patent Term Extension in Russia
BRIC WALL BLOG
July 19, 2013
Supplementary Protection Certificates and Pediatric Extensions in Croatia
BRIC WALL BLOG
July 10, 2013
New Russian Intellectual Property Court is Open
BRIC WALL BLOG
July 05, 2013
International Survey of the Patentability of Genes, Proteins and Other Genetic Materials
BRIC WALL BLOG
June 25, 2013
Recent Brazilian Federal Court Decision Involving Genetic Heritage and Traditional Knowledge
BRIC WALL BLOG
June 19, 2013
Proposed Increase in Official Fees in Connection with Patent Filings in India
BRIC WALL BLOG
June 07, 2013
Section 3(d) of the Indian Patents Act – Part I
BRIC WALL BLOG
May 30, 2013
Examination of Pharmaceutical Patent Applications by ANVISA In Brazil
BRIC WALL BLOG
May 23, 2013
Understanding Chinese Inventor Reward and Remuneration